Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14207 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von B Pernas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Department of Internal Medicine, University Hospital of A Coruña, A Coruña, Spain. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antifungal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Institute of Health Carlos III.
Abstract (Originalsprache)
Objectives
Our aim was to describe the frequency and severity of infectious complications after chimeric antigen receptor (CAR) T‐cell therapy in patients with large B‐cell lymphoma (LBCL).
Methods
We retrospectively reviewed clinical records of LBCL patients treated with CD19‐targeted CAR T‐cell therapy from July/2018 to December/2021 at our institution, and identified all infectious episodes from CAR T‐cell infusion until disease progression, death or last follow‐up.
Results
Overall, 137 patients were included. Thirty six percent had received ≥3 previous lines of therapy and 26% an autologous hematopoietic cell transplantation (auto‐HCT). Cytokine release syndrome occurred in 87 (64%) patients. Antibacterial prophylaxis was not used in any patient; only 38% received antifungal prophylaxis. Sixty three infectious events were observed in 41 (30%) patients. Fifty two (83%) of the infectious events had at least one pathogen identified (bacteria [ n = 38], virus [ n = 11], and fungi [ n = 3]). Most of the infectious events occurred during hospitalization for CAR‐T treatment. Infection‐related mortality was observed in two patients. Independent risk factors for infection included male gender, previous auto‐HCT, ≥3 lines of treatment and pre‐lymphodepletion neutropenia.
Conclusions
Infections after CAR T‐cell therapy in patients with lymphoma are frequent but generally not severe. A conservative and tailored antimicrobial prophylaxis seems to be a safe approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Department of Internal Medicine, University Hospital of A Coruña, A Coruña, Spain.
- Department of Infectious Diseases, University Hospital Vall d'Hebron, Barcelona, Spain.
- Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.
- Department of Microbiology, University Hospital Vall d'Hebron, Barcelona, Spain.
- CIBER of Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.
ORCID-Profile: G Iacoboni, P Barba
Förderung
- Instituto de Salud Carlos III
- Institute of Health Carlos III
Zitieren
APA
Pernas, B., Iacoboni, G., Los-Arcos, I., Carpio, C., Márquez-Algaba, E., Sanchez-Salinas, M. A., Albasanz, A., Esperalba, J., Viñado, B., Camps, I. R., & Barba, P. (2024). Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis. European Journal of Haematology. https://doi.org/10.1111/ejh.14207
Vancouver
Pernas B, Iacoboni G, Los-Arcos I, Carpio C, Márquez-Algaba E, Sanchez-Salinas MA, et al. Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis. European Journal of Haematology. 2024. doi:10.1111/ejh.14207
BibTeX
@article{Pernas2024,
author = {Pernas, B and Iacoboni, G and Los-Arcos, I and Carpio, C and Márquez-Algaba, E and Sanchez-Salinas, M A and Albasanz, A and Esperalba, J and Viñado, B and Camps, I Ruiz and Barba, P},
title = {Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14207}
}
EUVIMED